Literature DB >> 10189635

Distribution of adrenergic receptor subtypes in the retractor muscles of the upper eyelid.

B Esmaeli-Gutstein1, B R Hewlett, R C Pashby, J Oestreicher, J T Harvey.   

Abstract

PURPOSE: To identify adrenergic receptor subtypes and their relative distribution in the retractor muscles of the upper eyelid, the levator palpebrae superioris, and the Müller muscle. The pattern of distribution of these receptors in the Müller muscle was further compared in patients with dysthyroid eyelid retraction and in normal subjects.
METHODS: Müller muscle specimens were collected from 19 patients undergoing ptosis correction and from 8 patients undergoing repair of dysthyroid eyelid retraction. Immunohistochemical staining for alpha 1-, alpha 2-, beta 1-, and beta 2-adrenergic receptors was performed using antihuman rabbit polyclonal antibodies.
RESULTS: alpha 2-Adrenergic receptors were the predominant subtype in the Müller muscle, and beta 1-adrenergic receptors were the predominant subtype in the levator muscle. There was no significant difference in the staining pattern between specimens collected from patients with dysthyroid eyelid retraction and those from normal subjects.
CONCLUSIONS: The interaction between the alpha 2 and beta 1 receptors in the upper eyelid retractor muscles may be important in the control of the upper eyelid position and may contribute to the development of dysthyroid eyelid retraction. Specific alpha 2 antagonists could be developed and may be effective pharmacologic agents for the treatment of eyelid retraction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10189635     DOI: 10.1097/00002341-199903000-00005

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  6 in total

1.  Lower lid entropion secondary to treatment with alpha-1a receptor antagonist: a case report.

Authors:  Salman Waqar; Peter Simcock
Journal:  J Med Case Rep       Date:  2010-03-02

Review 2.  A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options.

Authors:  Jason Bacharach; Wendy W Lee; Andrew R Harrison; Thomas F Freddo
Journal:  Eye (Lond)       Date:  2021-04-29       Impact factor: 3.775

3.  Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.

Authors:  David L Wirta; Michael S Korenfeld; Shane Foster; Robert Smyth-Medina; Jason Bacharach; Shane R Kannarr; Mark J Jaros; Charles B Slonim
Journal:  Clin Ophthalmol       Date:  2021-10-08

4.  An Alternative Algorithm for Müller Muscle Conjunctival Resection Surgery for Blepharoptosis Management.

Authors:  Gamze Ozturk Karabulut; Korhan Fazil; Orcun Sonmez; Zehra Karaagac Gunaydin; Kubra Serefoglu Cabuk; Isil Pasaoglu; Muhittin Taskapili
Journal:  Beyoglu Eye J       Date:  2019-12-23

5.  Palpebral Fissure Response to Phenylephrine Indicates Autonomic Dysfunction in Patients With Type 1 Diabetes and Polyneuropathy.

Authors:  Thomas Arendt Nielsen; Carl Uggerhøj Andersen; Henrik Vorum; Sam Riahi; Rok Sega; Asbjørn Mohr Drewes; Jesper Karmisholt; Poul Erik Jakobsen; Birgitte Brock; Christina Brock
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

6.  Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results.

Authors:  Jason Bacharach; David L Wirta; Robert Smyth-Medina; Michael S Korenfeld; Shane R Kannarr; Shane Foster; Mark J Jaros; Charles B Slonim
Journal:  Clin Ophthalmol       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.